BRIEF published on 11/24/2025 at 09:05, 10 days 20 hours ago Nabaltec AG Q3 Performance Analysis and Outlook Nabaltec AG Q3 Performance Viscosity Optimized Hydroxides Boehmite Revenues Environmental Flame Retardants
PRESS RELEASE published on 11/24/2025 at 09:00, 10 days 20 hours ago Original-Research: Nabaltec AG (von NuWays AG): BUY NuWays AG releases research update on Nabaltec AG, reporting Q3 results in line with expectations and solid margins. Key takeaways and outlook discussed NuWays AG Q3 Results Nabaltec AG Investment Advice FCF Generation
BRIEF published on 11/20/2025 at 10:05, 14 days 19 hours ago Nabaltec AG Reports Stable Earnings Amid Revenue Dip in 2025 EBIT Margin Revenue Decline Q3 Results Nabaltec AG 2025 Earnings
PRESS RELEASE published on 11/20/2025 at 10:00, 14 days 20 hours ago Nabaltec AG with continued solid earnings power and a slight decline in revenues in the third quarter of 2025 Nabaltec AG reports solid earnings with a slight revenue decline in Q3 2025. Revenue forecast adjusted for 2025 expecting a maximum 2% decrease compared to the previous year Forecast Revenue Decline Earnings Nabaltec AG Q3 2025
BRIEF published on 08/22/2025 at 09:05, 3 months 13 days ago Nabaltec AG Releases Q2 Figures, Maintains "Buy" Rating Gross Margin BUY Rating Nabaltec AG Q2 2025 Results Specialty Alumina
PRESS RELEASE published on 08/22/2025 at 09:00, 3 months 13 days ago Original-Research: Nabaltec AG (von NuWays AG): BUY NuWays AG releases a research update on Nabaltec AG, highlighting Q2 results and future prospects, recommending a BUY. Key points include demand trends, improved gross margin, and cash position NuWays AG Investment Recommendation Research Update Q2 Results Nabaltec AG
BRIEF published on 08/21/2025 at 10:05, 3 months 14 days ago Nabaltec AG Reports Decline in First Half of 2025 EBIT Margin Q2 Results Nabaltec AG Investment Plans 2025 Revenue
PRESS RELEASE published on 08/21/2025 at 10:00, 3 months 14 days ago Nabaltec AG publishes interim report January to June 2025 Nabaltec AG published its interim report January to June 2025, reporting a revenue decrease of 1.7% and EBIT margin of 8.4%. Forecast for 2025: Revenue decline of up to 2% with EBIT margin expected in the range of 7% to 9% EBIT Margin Forecast Revenue Decrease Interim Report Nabaltec AG
BRIEF published on 08/05/2025 at 09:05, 3 months 30 days ago Nabaltec AG Faces Sales Decline Yet Remains Promising Sales Decline Long-term Growth Nabaltec AG Foreign Exchange Aluminum Hydroxide
PRESS RELEASE published on 08/05/2025 at 09:00, 3 months 30 days ago Original-Research: Nabaltec AG (von NuWays AG): BUY Nabaltec AG lowers FY25 sales guidance due to FX effect and weaker demand, maintains FY EBIT margin guidance. Q2 sales decrease, but core product demand remains strong. Company offers low valuation and healthy balance sheet Valuation Nabaltec AG Q2 Sales FY25 Sales Guidance Core Product Demand
Published on 12/05/2025 at 02:35, 3 hours 25 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 5 hours ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 6 hours 55 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 7 hours ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 03:30, 2 hours 30 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 6 hours 9 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 9 hours 35 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 9 hours 45 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 10 hours 50 minutes ago SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance
Published on 12/04/2025 at 18:00, 12 hours ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 12 hours 15 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 12 hours 16 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 22 hours 59 minutes ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 12 hours ago Declaration of voting rights at the end of November 2025
